Purpose: The primary aim was to compare the diagnostic performance of PET/MRI (performed with basic anatomical MRI sequences) in detecting sites of disease in adult patients with lymphoma compared with the current standard of care, PET/CT. Secondary aims were to assess the additional value of diffusion-weighted imaging to PET/MRI in disease detection and to evaluate the relationship between the standardized uptake value on PET/ MR and the apparent diffusion coefficient on diffusion-weighted imaging. Methods: Sixty-eight studies in 66 consecutive patients with histologically proven Hodgkin or non-Hodgkin lymphoma were prospectively evaluated. Each patient had whole body PET/CT, followed by whole body PET/MR. Two experienced readers independently evaluated the PET/MRI studies, and two other experienced readers independently evaluated PET/CT. Site of lymphoma involvement and SUVmax at all nodal sites more avid than background liver were recorded. Readers provided stage (in baseline cases) and disease status (remission vs active disease). The apparent diffusion coefficient mean value corresponding to the most avid PET site of disease was recorded. Results: Ninety-five nodal and 8 extranodal sites were identified on both PET/CT and PET/MRI. In addition, 3 nodal and 1 extranodal sites were identified on PET/MRI. For positive lesion detection, reader agreement in PET/MR was perfect between the 2 readers and almost perfect between PET/CT and PET/MR (k > 0.978). Intermodality agreement between PET/CT and PET/MRI was also near perfect to perfect for staging/disease status k = (0.979-1.000). SUVmax from PET/CT and PET/MRI correlated significantly (Spearman rho correlation coefficient, 0.842; P < 0.001). Diffusion-weighted imaging did not alter lesion detection or staging in any case. A negative correlation was demonstrated between ADC mean and SUVmax (Spearman rho correlation coefficient r, −0.642; P < 0.001). Conclusions: PET/MRI is a reliable alternative to PET/CT in the evaluation of patients with lymphoma. Diffusion-weighted imaging did not alter diagnostic accuracy. With comparable accuracy in detection of disease sites and added benefit of radiation dose reduction, PET/MRI has a potential to become part of routine lymphoma imaging.
L ymphoma is a common hematologic malignancy with 386,000 new cases of non-Hodgkin lymphoma (NHL) and 66,000 new cases of Hodgkin lymphoma diagnosed worldwide in 2012. In the same year, lymphoma accounted for 2.3% of all cancer deaths worldwide. 1 Therapeutic developments and advances in diagnostic imaging have led to a trend of increasing survival.
PET/CT use has increased considerably over recent years with extensive evidence in existence to support positive impact on staging and response assessment in Hodgkin lymphoma and NHL. [2] [3] [4] [5] Patients with lymphoma may undergo multiple CT and PET/ CT examinations during the course of investigation and treatment.
There has been recent interest in the potential application of whole body MRI in lymphoma, as a radiation-free comparable modality to PET/CT, including the measurement of the apparent diffusion coefficient (ADC) with some promising results. 6, 7 However, FDG PET/CT remains the reference standard for lymphoma staging, as there is a lack of larger scale studies demonstrating unequivocal benefit of whole body MRI-DWI. 8 Hybrid PET/MRI imaging systems have been recently introduced to allow simultaneous acquisition of PET and MRI data. In these scanners, MRI sequences (2-point Dixon) are used for attenuation correction instead of CT, and other MRI sequences are acquired for anatomical correlation. 9 Several feasibility studies have evaluated patients with various tumor types when comparing PET/CT and PET/MR. 10, 11 Generally, PET/MR has been shown to be equivalent to PET/CT in localizing tumor and metastases, with a variable proportion of additional lesions detected with the benefit of superior soft tissue resolution on PET/MRI. Catalano et al 12 studied 134 patients with cancer who had PET/CT and PET/MR on the same day and found additional findings on PET/MR affecting clinical management in 17.4% of cases.
There is a lack of published data regarding ability of PET/ MRI to evaluate adult patients with lymphoma. The purpose of this study was to specifically evaluate the diagnostic performance of lesion detection and disease status in adult lymphoma patients on PET/MRI, compared with the current standard of care of PET/CT. The relationship between SUV and ADC was also evaluated.
SUBJECTS AND METHODS
This study underwent approval from the local institutional ethics review board. Consecutive patients undergoing clinically indicated whole body 18 F-FDG PET/CT (for staging or response assessment of lymphoma) were identified and invited to have the additional PET/MRI study.
Patients received an intravenous injection of 18 F-FDG and underwent PET/CT, followed by PET/MR with residual signal from the initial injection.
Between May 2012 and January 2014, approximately 68 scans were performed in 66 patients (45 male and 21 female subjects, with 2 men being studied twice during the study period) who underwent PET/CT and additional PET/MRI. The mean age of the final study group was 42.8 years (range, 18-87). The indications for scanning were mixed (pretreatment [n = 18] and posttreatment). Types of lymphoma studied were Hodgkin (n = 27), DLBCL (n = 25), FL (n = 1), mixed DLBCL and FL (n = 1), and others (n = 
Image Acquisition PET/CT Examination
The PET/CT scan was performed in fasted patients using a Discovery VCT 64-slice PET/CT scanner (GE Healthcare, Milwaukee, WI) 60 minutes after intravenous injection of 5.5 MBq/kg of 18 F-FDG (mean, 64 minutes; range, 50-90; ±7.8). Emission scan was acquired as per our usual clinical protocol to cover vertex to midthighs. Mean injected FDG dose was 369.3 MBql (range, 160-421; ±42.5). PET images were reconstructed with iterative reconstruction with 2.5 minutes per bed position.
CT was performed according to a standard protocol with the following parameters: 140 keV, modulated 30 to 300 mAs, pitch 1.375, and section thickness 2.5 mm. The mean duration of the PET CT studies was 20.4 minutes (range, 15.5-22.5; ±1.4).
PET/MRI Examination
Patients were then transferred to the PET/MR scanner (3 T Biograph mMR; Siemens, Erlangen, Germany) located in a different building, where an integrated PET and MR acquisition was performed, as soon as possible after the PET/CT examination, mean interval of 136 minutes (range, 90-243 minutes; ±28.6) after original FDG injection. Four-tissue class (soft tissue, fat, lung, and air) attenuation correction maps were calculated from 2-point Dixon sequences. The MR protocol for each patient included axial T2-weighted HASTE, axial diffusion (DWI, b = 0, 400, 800) and coronal T1-weighted 3-D interpolated breath-hold examination (VIBE). Studies were performed at 3 minutes per bed position. The scan duration ranged between 20 and 30 minutes, depending on time for shimming. Thirteen minutes of additional scan time for the acquisition of DWI.
Image Interpretation
Two radiologist readers, (10 and 4 years experience, respectively, in reporting PET/CT) independently evaluated the PET/ CTs, with access to clinical history but without access to the PET/ MRI study.
Two other radiologist readers (both with 3 years experience in reporting PET/MRI) independently read the PET/MRI studies, also with access to clinical history but without access to the PET/CT performed on the same day.
Nodal stations were divided into the following groups: right and left cervical, supraclavicular, subpectoral, axillary, mediastinal, liver hilum, splenic hilum, mesenteric, retroperitoneal, right and left iliac, and inguinal. Sites of extranodal disease were also recorded.
Lesion uptake was determined as significant if higher than liver background except in those regions where high physiological tracer activity is expected, for example, tonsils, in which cases abnormal uptake was defined as specific for those regions.
Tumor staging was determined for baseline PET/CT and PET/MRI scans. For posttreatment scans, disease status was divided into metabolic remission and metabolic active disease.
Although PET/CT was the reference standard, review in consensus and review of follow-up imaging were performed for any discrepant cases.
PET/CT
Images of a maximum intensity projection of the attenuation correction PET study and multiplanar images of the AC PET, whole body CT, and free-breathing lung CT data were viewed on a GE Advantage Workstation, Adw 4.4. A volume of interest was drawn within the right hepatic lobe for liver SUVmax. Sites of nodal disease were recorded if FDG uptake was greater than liver SUVmax.
PET/MRI
Images of a maximum intensity projection of the attenuation correction PET study and multiplanar images of the AC and MRI sequences were reviewed on a workstation using OsiriX (http:// www.osirix-viewer.com/) software. Both readers reviewed all scans in a sequential manner (summarized in Fig. 1 ), initially viewing the PET images together with T2 HASTE, T1 VIBE, and fused PET/T2 HASTE sequences. After this, each reader reviewed the DWI sequences (b = 0, 400, 800 and ADC images) alongside the PET and T1 and T2 sequences. Sites of nodal disease were recorded if FDG uptake was greater than liver SUVmax. Any change based on review of DWI was also recorded. Regions of interest were drawn within the right hepatic lobe for liver SUVmax. Regions of interest were drawn around FDG avid nodes on single axial slices, ensuring the SUVmax was recorded.
Quantitative evaluation of ADC was performed on the single lesion (if convincingly visible on the DWI), which demonstrated the greatest SUVmax value in each study. A single reader displayed the T2 HASTE image, PET AC image, b800, and ADC map. Using all data combined, a region of interest was drawn on the ADC map to provide a value of ADC mean for the most avid lesion on the PET study.
Statistical Analysis
Statistical analysis was performed using dedicated software (SPSS version 21; SPSS Inc., Chicago, IL).
The generalized kappa statistic (k) was used to determine PET/MR interobserver agreement and intermodality agreement (PET/CT vs PET/MR) for staging and sites of nodal involvement, considering: k < 0.2 as slight agreement, k = 0.21-0.40 as fair agreement, k = 0.41-0.60 as moderate agreement, k = 0.61-0.80 as substantial agreement, and k = 0.81-1.00 as almost perfect to perfect agreement. 13 SUV results were evaluated by nonparametric correlation analysis, using the Spearman rank correlation coefficient to examine the association between SUVmax from PET/CT and PET/MRI. SUV and ADC results were evaluated using nonparametric correlation analysis, using the Spearman rank correlation coefficient to examine the association between SUVmax and ADC value from PET/MRI.
A Bland-Altman plot was used to assess intermodality agreement on SUVmax values.
Statistical significance was accepted for P < 0.05.
RESULTS

Nodal and Extranodal Disease Nodal Disease
A total of 95 sites of nodal disease were reported as positive on both PET/CT and PET/MRI. In 2 cases (of NHL), there were a total of 3 nodal disease sites reported as called positive by both PET/MRI readers but not reported by either PET/CT reader. In the first case, the nodal sites were in the mesentery and retroperitoneum (Fig. 2) , and in the second case, the positive nodes were in the axilla.
Fifteen of the 27 patients with Hodgkin lymphoma had FDG avid disease (44 nodal and 2 extranodal).
Extranodal Disease
There were 4 studies identifying splenic involvement on PET/CT and PET/MRI (2 in Hodgkin lymphoma). Two cases of marrow involvement were called positive on both modalities (both were in patients with Hodgkin lymphoma).
In 8 studies, there were 8 sites of extranodal disease on PET/ CT (2 were in patients with Hodgkin lymphoma) and 9 sites of extranodal disease in 8 studies on PET/MRI. In 1 case, where a patient had lung and adrenal involvement, both PET/CT and PET/ MRI readers called lung involvement positive. However, neither PET/CT reader called positive disease in the adrenal gland, whereas both PET/MRI readers identified disease at this site (Fig. 3) . Review of follow-up imaging confirmed the presence of extranodal adrenal disease (increased size and metabolic activity). Table 1 shows nodal and extranodal sites identified by each reader, and Table 2 shows the kappa analysis for agreement for detection of nodal sites between readers and between PET/CT and PET/MRI.
Staging of Baseline Studies and Disease Status Posttreatment
Staging was concordant between PET/CT readers and between PET/MRI readers in all 18 baseline cases. A single case where right axillary nodes were called positive on PET/MRI but not on PET/CT was deemed a true positive but did not alter staging 
PET/MRI and PET/CT in Lymphoma Evaluation in this patient. In the posttreatment cohort, all cases were concordant, with the exception of 1 case where mesenteric and retroperitoneal nodes were called positive, resulting in a discrepancy where both PET/MRI readers recorded both sites (metabolically active disease), and both PET/CT readers recorded no disease (metabolic remission). Table 3 shows the kappa analysis of agreement in staging/ response assessment between readers and between PET/CT and PET/MRI
Diffusion-Weighted Imaging
None of the 68 cases had additional nodal or extranodal sites identified with DWI. The staging categories with each modality are shown in Table 4 .
A moderate inverse correlation was found between the ADC mean and SUVmax (correlation coefficient, Spearman rho correlation coefficient, r = −0.642; P < 0.001 [95% confidence interval (CI) for r, −0.339 to −0.824]). This was evaluated in 27 studies where the most avid lesion on PET corresponded to a measurable lesion on the ADC map (Fig. 4) .
SUVmax Analysis
There was a strongly positive correlation between SUVmax on PET/CT and on PET/MRI (Fig. 5) , with Spearman rho correlation coefficient of 0.842 (P < 0.001 [95% confidence interval (CI) for r, 0.771-0.892]).
The Bland-Altman analysis ( 
DISCUSSION
This study demonstrated that PET/MR had comparable ability to detect nodal and extranodal disease in a range of lymphomas and was equivalent in providing the overall stage and disease status when compared with the reference standard of PET/CT.
There were a small number of discrepant cases where PET/ MR detected additional lesions. Because these areas were not subjected to further biopsy, it is not possible to give a definitive answer as to whether these were genuine sites of disease. Three nodal sites detected in the abdomen and axilla on PET/MRI and not on PET/CT may have been due to increased tracer accumulation with delayed acquisition. However, an additional site of extranodal (adrenal) disease reported on PET/MRI had the benefit of follow-up PET/CT imaging (showing a continued increase in size and metabolic activity), which suggested this was a true site of disease. This adrenal lesion may have been identified because of a combination of better anatomical detail on MRI and increased tracer accumulation within the lesion from the delayed acquisition. Therefore, a definite benefit from the modality alone cannot be confirmed.
Interreader agreement was near perfect to perfect for nodal, extranodal, and staging for readers of PET/MRI and for readers of PET/CT.
Semiquantitative assessment on PET/MRI (measurement of SUVmax) demonstrated excellent correlation with the same data from PET/CT. These 2 features are essential components for validation of PET/MRI before adoption into clinical trials and routine clinical use.
The findings from this study are in agreement with those from a pilot study of 28 patients with lymphoma by Heacock et al, where PET/CT and PET/MRI staging was concordant in 96.4%. 14 The 1 case of discrepancy in that study involved PET/MRI detecting bone marrow involvement not identified on PET/CT. In our study, only 2 patients had bone marrow involvement, both correctly identified on PET/CT and PET/MRI. Our study also evaluated interreader agreement in this population, which had not previously been reported.
Diffusion-weighted imaging when assessed in a qualitative manner provided no additional value to PET in detecting sites of disease or in altering staging or disease status. Similar findings of a lack of benefit of DWI in lesion localization in addition to routine PET/ MRI sequences has been reported in a range of tumors. In 25 oncology patients, Buchbender et al identified 49 lesions with both PET/ MRI alone and PET/MRI combined with DWI. 15, 16 There may be a potential role for DWI improving diagnostic accuracy in lymphomas with variable FDG uptake, although such types, for example, MALT lymphoma, were not represented in our study population. 17 Only the most avid lesions in each PET/MRI study were chosen, and the results demonstrated a negative correlation between these 2 imaging biomarkers. In a small study of patients with DLBCL, ADC mean correlated inversely with the SUVmax (r = −0.74; P < 0.05). 18 In a mixed population of patient with DLBCL and FL, Wu et al found significant correlations between ADCmin and SUVmax. 19 The relationship was also demonstrated in pediatric Hodgkin lymphoma. 20 However, other studies have found no significant correlation between ADC and SUV metrics. 21, 22 The lack of an exact and consistent correlation can be explained by the different physiological mechanisms, which each biomarker examines. Although SUV is well recognized as a marker of tumor glucose metabolism and, therefore, cellular proliferation, the components contributing to an ADC value are more complex and include cellular density, extracellular fibrosis, the shape and size of the intercellular spaces, and other microscopic tissue/tumor organizational characteristics. These ADC components can be considered to reflect tumor aggressiveness, and a relationship between tumor proliferation and tumor aggressiveness is widely recognized.
Although the DWI did not alter disease detection, there is potential for this to provide prognostic information in patients with lymphoma. A recent study in Hodgkin lymphoma found that pretreatment ADC was predictive of site-specific interim response to chemotherapy. 23 Aside from the comparable diagnostic performance as shown in this study, there are several other major issues to consider with regard to implementing PET/MRI into clinical practice. Recently described in a pediatric population, PET/MRI can offer significant ionizing dose reduction: 73% (±11%) reduction in total effective dose in 1 study. 24 The length of scanning time is comparable for PET/MRI and PET/CT when anatomical sequences alone are performed. Diffusion-weighted imaging significantly increased scan time for PET/MRI, although this study showed no additional benefit of acquiring these images. There are considerable start-up costs for introducing a PET/MR service, and the cost of a PET/MR scan is greater than PET/CT, for example, £1300 versus £950 in the UK.
Limitations and Further Considerations
Because of the acquisition of PET/MRI from the radiotracer injected for the preceding PET/CT and the location of the PET/MRI being in a different building within our site, there was a variable delay of acquisition time for the PET. This could have increased the uptake in some sites of disease relative to background because of tracer accumulation. An overestimation of FDG uptake has been reported when PET/MRI is performed after PET/CT, 10 although others have described a decrease in SUVmax within lesions. 25 A reduced time interval between the 2 studies may have minimized this effect; however, although 2 more nodal and one extranodal sites were deemed positive on PET/MRI, in only 1 case did this result in altered response status. The finding of additional nodal stations being called positive with PET/MRI was not described by Heacock et al, possibly related to a shorter duration between injection and uptake time for PET/MRI when compared with our study. 14 Patients were selected on the basis of consecutive clinically indicated PET/CTs for lymphoma assessment. These were not limited to baseline or particular types of lymphoma, and therefore, there was heterogeneity in the patient population. This was to create a large enough cohort to generate meaningful results and reflect clinical workload within the department. Nonetheless, this could have created inhomogeneity and, thus, bias in the study population.
Clinically, a 5-point score has been widely implemented to quantify response assessment by measuring SUVmax relative to mediastinal blood pool and background liver uptake 26 with good interreader agreement. [27] [28] [29] The score is based on the most avid site of disease with reference to mediastinal blood pool and liver SUVmax. In this study, only uptake greater than liver background (equivalent to a score of 4 or more) was used to indicate positive sites of disease. A score of 4 is accepted as indicating active metabolic disease, whereas uptake greater than mediastinum background but less than liver background (score of 3) is in many cases linked with good outcome and probable remission. SUVmax is a more robust comparator over time, which was useful, given extra delay with imaging the PET/MRI studies. Prolonged uptake times lead to an increased washout in normal structures, which appear more marked in the mediastinal blood pool. In 99 patients, Chin et al 30 demonstrated that the mean SUVs on 3-hour versus 1-hour images were significantly lower for aortic blood pool 13% (P < 0.0001) but found no significant difference in the liver (1%, P = 0.85).
PET/MRI allows an opportunity for numerous MRI sequences to be acquired for diagnostic purposes. At the most basic level, the MRI component can provide anatomical localization of FDG uptake. However, there is potential for more advanced, functional sequences to improve on PET/CT in lesion detection. We did not find DWI to be of help but did not investigate other MRI sequences, for example, STIR, for bone marrow involvement in the interest of reducing scan time. Despite this, both cases with marrow involvement on PET/CT were also correctly identified as such on PET/MRI. Therefore, we have shown compelling data that PET/MRI is at least equivalent to PET/CT in detection of nodal disease and extranodal disease and in providing staging/disease status. Future studies may include additional MR sequences to localize disease and study the predictive and prognostic benefits of using PET/MRI.
CONCLUSIONS
PET/MRI is a reliable alternative to PET/CT in the evaluation of patients with lymphoma. A small number of additional sites of disease were detected with PET/MRI, although this may have been due to delayed acquisition time.
There is scope to gain additional prognostic information from PET/MRI not available on PET/CT, although these data do not influence lesion detection or staging; DWI offered no diagnostic benefit in this population. A weakly negative but significant correlation between SUVmax and ADC mean was compatible with some other published studies. Given the inherent benefits of ionizing radiation dose reduction and the fact that patients will often require multiple scans, PET/MRI has the potential to become part of routine lymphoma imaging.
